Apyx Medical Corporation (APYX) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
APYX Revenue Growth
Revenue Breakdown (FY 2025)
APYX's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
APYX Revenue Analysis (2014–2025)
As of May 8, 2026, Apyx Medical Corporation (APYX) generated trailing twelve-month (TTM) revenue of $55.8 million, reflecting explosive growth of +31.7% year-over-year. The most recent quarter (Q1 2026) recorded $12.4 million in revenue, down 35.2% sequentially.
Looking at the longer-term picture, APYX's 5-year compound annual growth rate (CAGR) stands at +13.8%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $52.8 million in 2025, representing a new all-time high.
Revenue diversification analysis shows APYX's business is primarily driven by OEM (100%). With over half of revenue concentrated in OEM, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including SSKN (-5.2% YoY), ARAY (-7.9% YoY), and INVA (+13.6% YoY), APYX has outperformed the peer group in terms of revenue growth. Compare APYX vs SSKN →
APYX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| APYXCurrent | $56M | +31.7% | +13.8% | -12.2% | |
 SSKN | $34M | -5.2% | +1.2% | -27.6% | |
 ARAY | $459M | -7.9% | +3.7% | 1.7% | |
 INVA | $425M | +13.6% | +4.8% | 38.5% | |
 AEYE | $40M | +14.5% | +14.5% | -7.9% | |
 INMD | $370M | -4.5% | +12.4% | 23.0% |
APYX Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $52.8M | +9.9% | $19.0M | 36.0% | $-6,446,000 | -12.2% |
| 2024 | $48.1M | -8.1% | $29.4M | 61.0% | $-18,845,000 | -39.2% |
| 2023 | $52.3M | +17.6% | $33.8M | 64.5% | $-17,259,000 | -33.0% |
| 2022 | $44.5M | -8.3% | $29.1M | 65.4% | $-23,562,000 | -52.9% |
| 2021 | $48.5M | +75.1% | $33.6M | 69.3% | $-14,448,000 | -29.8% |
| 2020 | $27.7M | -1.9% | $17.5M | 63.2% | $-20,083,000 | -72.5% |
| 2019 | $28.2M | +69.2% | $19.1M | 67.6% | $-20,869,000 | -73.9% |
| 2018 | $16.7M | -57.1% | $10.8M | 64.7% | $-13,600,000 | -81.5% |
| 2017 | $38.9M | +6.2% | $19.8M | 50.8% | $-5,265,000 | -13.5% |
| 2016 | $36.6M | +24.1% | $17.9M | 48.9% | $-3,792,000 | -10.4% |
See APYX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs APYX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare APYX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonAPYX — Frequently Asked Questions
Quick answers to the most common questions about buying APYX stock.
Is APYX's revenue growth accelerating or slowing?
APYX revenue is accelerating at +31.7% year-over-year, exceeding the 5-year CAGR of +13.8%. TTM revenue reached $56M. Growth momentum has increased versus prior periods.
What is APYX's long-term revenue growth rate?
Apyx Medical Corporation's 5-year revenue CAGR of +13.8% reflects the sustained expansion pattern. Current YoY growth of +31.7% is above this long-term average.
How is APYX's revenue distributed by segment?
APYX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.